Clinical Trial Update: A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 study of tarextumab (OMP-59R5) in combination with etoposide and platinum therapy in Stage IV small cell lung cancer was terminated, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• tarextumab (tarextumab)

Snippet

Sponsor: OncoMed Pharmaceuticals, Inc. | Conditions: Stage IV Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-05-01